

Press Release

Straumann completes the offer to the shareholders and warrant holders of Biora and extends the acceptance period

- **Straumann's offer to the shareholders and warrant holders of Biora has been accepted to such extent that Straumann holds approximately 87 percent of the shares and votes of Biora.**
- **Straumann completes the offer and extends the acceptance period until and including 6 June 2003.**

Straumann Holding AG's offer, made through its wholly-owned subsidiary Institut Straumann AG, to the shareholders and warrant holders of Biora AB (publ) has been accepted to such extent that Straumann holds 20,669,462 shares in Biora, representing approximately 87 percent of the total number of shares and votes in Biora, and 785,000 warrants in Biora, representing approximately 98 percent of the total number of warrants in Biora. Straumann has acquired all its shares and warrants in Biora by way of the offer.

Straumann has decided to complete the offer even though all of the conditions for completing the offer have not been fulfilled. Straumann has also decided to purchase Biora shares on the market.

In order to enable those shareholders and warrant holders who have not already accepted the offer to do so, Straumann has decided to extend the acceptance period until 6 June 2003.

- Straumann offers SEK 17 in cash for each Biora share.
- Straumann offers SEK 1.50 in cash for each outstanding Biora warrant issued under the employee warrant programme 2001/2004.

Settlement in relation to shareholders and warrant holders who have accepted the offer during the initial acceptance period is expected to commence on or around 3 June 2003. Settlement in relation to shareholders and warrant holders who accept the offer during the extended acceptance period is expected to commence on or around 13 June 2003.

The Board of Directors of Biora has unanimously recommended that Biora shareholders and warrant holders accept the offer.

In the event that Straumann acquires shares in Biora to such extent that its holding on a fully diluted basis exceeds 90 percent of the total number of shares and votes of Biora, Straumann

intends to initiate compulsory acquisition to acquire the remaining shares in Biora and to seek de-listing of Biora's shares from the Stockholm Exchange in connection therewith.

Waldenburg, 26 May 2003

For further information please contact:

Straumann Holding AG

Gilbert Achermann, CEO

Tel: (41) 61 965 11 11

Martin Gertsch, CFO

Tel: (41) 61 965 11 11

This announcement does not constitute an offer or invitation to exchange or sell or an offer to exchange or purchase any securities.

The Offer is not being made, directly or indirectly, in or into the United States of America, Canada, Australia or Japan, and it may not be accepted in or from the United States, Australia, Canada or Japan. Copies of this press release and any related materials are not being and should not be mailed or otherwise distributed or sent in or into the United States of America, Canada, Australia or Japan.

The Offer is furthermore not directed to persons whose participation in the offering requires that further offer documents are issued or that registration or other measures are taken, other than those required under Swedish law. No document relating to the Offer may be distributed in or into any country where such distribution or offering requires any of the aforementioned measures to be taken or would be in conflict with any law or regulation of such a country. In the event of such distribution or offering still being made, an acceptance form sent from such a country may be disregarded.

Biora shareholders and warrant holders are advised to read the offer documentation, as it will contain important information relating to the Offer.

This press announcement is a translation from the Swedish language. In the event of any discrepancy between the Swedish version and the English version, the Swedish version shall prevail.

This press release may not be released, publishes or distributed, directly or indirectly, in or into the United States, Australia, Canada or Japan.

The Straumann Group, with headquarters in Waldenburg, Switzerland, is a leader in the field of implant dentistry. Straumann develops, produces and markets products worldwide for oral implantology (ITI® DENTAL IMPLANT SYSTEM, instruments) in cooperation with the International Team for Oral Implantology (ITI), leading hospitals, research institutes and universities. Through the acquisition of Kuros Therapeutics, Straumann gained the necessary competency to develop tissue regeneration products for the dental market. Straumann products are all manufactured in Switzerland. The company is represented by subsidiaries in 14 countries worldwide, and in 35 countries by distributors. Sales in fiscal year 2002 amounted to CHF 275 million. Straumann has 750 employees worldwide, of whom 220 are employed at the company's headquarters in Waldenburg/Switzerland, and 160 at its production plant in Villeret/Switzerland.

Straumann Holding AG, Hauptstrasse 26, 4427 Waldenburg, Switzerland

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

e-mail: investor_relations@straumann.com or info@straumann.com

Homepage: www.straumann.com
